



2 November 2012

Dr Richard Chadwick
The General Manager
Adjudication Branch
Australian Competition and Consumer Commission
By email: adjudication@acc.gov.au

436 Johnston Street
Abbotsford Victoria 3067
Australia

PO Box 18095
Melbourne Victoria 8003
Australia

Tel: +61 03 9721 6000
Fax: +61 03 8761 2442
www.gsk.com.au

Dear Mr Chadwick

**RE: Medicines Australia Limited application for revocation and substitution
A91316-A91320 - PRE-DECISION CONFERENCE**

GlaxoSmithKline would like to register attendance for the Medicines Australia Limited application for revocation and substitution pre-decision conference.

Attendees for the Melbourne Session representing GlaxoSmithKline are:

Lisa Maguire, Associate Director Corporate Affairs (Spokesperson)
Tel: 0449 950 745
Email: lisa.a.maguire@gsk.com

Glynn Mayne, Compliance Manager
Tel: 0449 953 610
Email: glynn.m.mayne@gsk.com

GSK made a submission to the ACCC in July 2012 to support the authorisation of the Medicines Code of Conduct as presented to the ACCC by Medicines Australia.

I have attached this submission as this is the same comment that we would like to have tabled and circulated at the pre-decision conference. Part of this submission was the results of a consumer perception study relevant to the submission. This is attached also. We are attending to verbally support these statements.

Kind regards

Lisa Maguire
Associate Director Corporate Affairs
GlaxoSmithKline Australia.